Monday, November 8, 2021
- 8:30AM-10:30AM
-
Abstract Number: 1030
Critical Illness in Modern Rheumatology: Analysis of Admissions to Australian and New Zealand ICUs
Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)- 8:30AM-10:30AM
-
Abstract Number: 1110
Cryopyrin-associated Periodic Syndromes: GOSH and National Amyloidosis Centre Experience
Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)- 8:30AM-10:30AM
-
Abstract Number: 1096
CSF-specific CD8 T Cell Clonal Expansion in Neurosarcoidosis
Miscellaneous Rheumatic & Inflammatory Diseases Poster II: Clinical Features & Diagnostics (1083–1117)- 8:30AM-10:30AM
-
Abstract Number: 1204
CXCL13 Outranges DAS28CRP and CRP as Predictor of Long-term Radiographic Status in Early Rheumatoid Arthritis
RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)- 8:30AM-10:30AM
-
Abstract Number: 1311
De Novo Psoriasis Can Be Reported at Any Timepoint in Early Axial Spondyloarthritis: An Analysis of 6 Years of Follow-up of the DESIR Cohort
Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes III: Comorbidities, Extra-muskuloskeletal Manifestations, & Related Conditions (1304–1328)- 8:30AM-10:30AM
-
Abstract Number: 1411
Decreased Use of Ultrasound Fast-track Pathways of Giant Cell Arteritis Due to COVID-19 Pandemic: A Potential Risk for Permanent Visual Loss
Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)- 8:30AM-10:30AM
-
Abstract Number: 1179
Determining Faculty vs. Fellow Preferences for ROSCE Milestone Assessments; Is It Time for a Change in Needs Assessment?
Professional Education Poster (1170–1195)- 8:30AM-10:30AM
-
Abstract Number: 1352
Deucravacitinib Efficacy in Psoriatic Arthritis (PsA) by Baseline DMARD Use: Exploratory Analysis from a Phase 2 Study
Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)- 8:30AM-10:30AM
-
Abstract Number: 1419
Development and Validation of a Patient Reported Outcome Measure for Giant Cell Arteritis
Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Giant Cell Arteritis & Polymyalgia Rheumatica (1391–1419)- 8:30AM-10:30AM
-
Abstract Number: 1215
Development of a Multivariable Prediction Model for Treatment Response to Etanercept in a Multi-centre Cohort of Patients with Established RA
RA – Diagnosis, Manifestations, & Outcomes Poster III: Prediction, Biomarkers, & Treatment Response (1196–1222)- 8:30AM-10:30AM
-
Abstract Number: 1239
Differences in Patient-Reported Outcomes Between Those Who Stay in Remission and Those Who Have Disease-Worsening Following Therapy Withdrawal in Patients with Rheumatoid Arthritis
RA – Treatments Poster II: PROs, Biomarkers, & Systemic Inflammation (1223–1256)- 8:30AM-10:30AM
-
Abstract Number: 1354
Differences in Real-World Patient Characteristics of 8921 Patients with Psoriasis with and Without Comorbid Psoriatic Arthritis Using the UK BADBIR Database
Spondyloarthritis Including PsA – Treatment Poster II: Psoriatic Arthritis I (1329–1363)- 8:30AM-10:30AM
-
Abstract Number: 1275
Digital Solution for Collection of Patient-reported Outcome Measures in Patients with Systemic Lupus Erythematosus: A Randomised, Crossover, Agreement Study
SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)